Dr. Siddhartha Kumar Mishra

Dr. Siddhartha Kumar Mishra |Clyto Access

Dr. Harisingh Gour Central University, India

Organizing Committee Member

Expertise: Elucidation of Molecular Mechanism of the Anticancer Effects of Natural Pharmaceutical Agents and Synthetic Drugs Against Human Malignancies

Biography: Dr. Mishra has published 30 scopus publications with 450 citations, and h & i index 12 each. The cumulative & average impact factor is 73 & 3.1. He has authored 2 book chapters and contributed to one USA Patent. He has published 24 abstracts in international seminars and conferences and 37 abstracts in national meetings. He has completed one research project and one ongoing EMR research project. He is a recipient of 3 international and 5 national awards. He is member of several academic bodies including Nominated Member of “International Natural Product Sciences Taskforce (INPST)” Poland (an International Consortium). He is in editorial board of 6 journals and reviewer for 17 journals. He has organized 8 conferences and seminars. The major research emphasis was on elucidation of molecular mechanism of the anticancer effects of natural pharmaceutical agents and synthetic drugs against human malignancies. Recently investigated the effect of a medicinal mushroom Inonotus obliquus against intestinal inflammation and colorectal cancer. The isolated molecule (ergosterol peroxide) is proposed for clinical trial. Another plant-based drug agent (cedrtol) showed potent anticancer effects against human leukemia and colorectal cancer cell lines. Andrographolide was identified to be potent anticancer agent by modulating p53 in human malignancies. Omeprazole (proton pum inhibitor) was reported to induce genetic instability in plants. Also worked on the oxidative stress induced neuronal cell death, aiming to explore the cellular and molecular mechanism involved in neuroprotection of onion extract and quercetin. Using the drug repositioning approach, a commonly used anesthesia, midazolam, was analyzed for its anticancer properties in human leukemia and colorectal cancer. Cancer genomics has been another area of research, in which, the association of IGF1R gene was assessed in correlation with breast cancer risk. Correlations between risk factors for breast cancer and genetic instability in cancer patients was identified. Impact of chemotherapy on various biochemical markers in breast cancer patients was also established. The recent focus is to prepare novel drug delivery system using DNA nanotechnology and using micellar lipids such as Self-Micellizing Anticancer Lipid (SMAL) nanoparticle. We further aim to generate traditional technologies for site-specific drug delivery and to prepare targeted drug agents for cancer therapy and prevention.

Related Conferences :

International Biotechnology and Pharmaceutical Industry Forum